Business
INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
Announced substantial progress with lead program, INO-3107, as potential treatment for Recurrent Respiratory Papillomatosis (RRP)Positive data announced from
About this update from Inovio Pharmaceuticals, Inc.
[{"type":"text","content":"Announced substantial progress with lead program, INO-3107, as potential treatment for Recurrent Respiratory Papillomatosis (RRP)Positive data announced from Phase 1/2 trialOrphan Drug Designation granted by European Union Breakthrough Therapy Designation granted by U.S. Food and Drug Administration (FDA)Received FDA feedback that data from completed Phase 1/2 trial can be used to submit Biological License Application (BLA) under accelerated approval programAnnounced plan to submit BLA to FDA under accelerated approval program in second half of 2024Announced clinical collaboration and supply agreement with Coherus BioSciences to advance development of INO-3112 in combination with LOQTORZI™ (toripalimab-tpzi)Combination therapy to be evaluated in a planned Phase 3 trial in patients with locoregionally advanced, high-risk, HPV-16/18-positive throat cancerClinical trial design submitted to FDA in first quarter 2024; feedback expected in second quarterReported positive Phase 1b results for INO-4201 as a potential Ebola booster vaccine for rVSV-ZEBOV (Ervebo®)Prioritized pipeline and reduced 2023 operating expenses by 48% from 2022Ended 2023 with $145.3 million in cash, cash equivalents, and short-term investmentsProjects cash runway into second quarter 2025Management will host conference call today at 4:30 p.m. ETPLYMOUTH MEETING, Pa., March 6, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results and operational highlights for the fourth quarter and full year ended December 31, 2023.\n\n \n \n \n \n \n \n\n \nINOVIO's President and Chief Executive Officer, Dr. Jacqueline Shea, said, \"The past year has been transformative as we've reshaped INOVIO into a company that is focused on commercializing its first product candidate and bringing the benefits of DNA medicine to patients. We've done so by focusing on the strengths of our platform and our strategic objectives: advancing candidates with scientific promise, achievable pathways to market, and strong commercial potential, and maintaining an ongoing commitment to financial discipline and operational excellence.\"\nDr. Shea continued, \"In the past year we have taken our lead candidate, I...